Prolia (Denosumab) Cost in New York 2026

What Is Denosumab and Why Does Cost Matter?

Denosumab (brand name Prolia) is a RANK-ligand inhibitor that reduces osteoclast-mediated bone resorption. The FDA approved it in 2010 for postmenopausal women with osteoporosis at high fracture risk, and it has since earned additional indications for bone loss in men receiving androgen-deprivation therapy and for glucocorticoid-induced osteoporosis. The drug is dosed at 60 mg subcutaneously every six months, which means a patient typically needs two injections per year.

The cost question is not academic. The key FREEDOM trial (N=7,868) showed that denosumab reduced new vertebral fracture risk by 68% over 36 months compared with placebo (relative risk 0.32 to 95% CI 0.26 to 0.41; P<0.001), making it one of the most effective agents in the osteoporosis armamentarium. [1] Missing doses because of cost carries real clinical consequences: abrupt discontinuation of denosumab is associated with rebound vertebral fractures, a finding highlighted in an FDA Drug Safety Communication. [2]

That downstream fracture risk makes affordability a medical issue, not merely a financial one. Patients in New York face a list price of approximately $1,500 per injection, but the actual out-of-pocket figure depends heavily on insurance type, income, and which assistance programs a provider enrolls the patient in at the time of prescribing. [3]

Prolia List Price vs. Real-World Cost in New York

The Amgen wholesale acquisition cost for Prolia in 2026 is approximately $1,500 per 60 mg prefilled syringe, which translates to roughly $3,000 per year before any rebates, insurance adjustments, or assistance programs apply. [4] That list price has risen substantially from the drug's 2010 launch price and now places Prolia among the more expensive injectable agents prescribed in primary care and endocrinology offices across the state.

At retail pharmacies in New York City, Long Island, and upstate regions, the cash-pay price without any discount mirrors the list price closely, hovering around $1,500 per dose in 2026. GoodRx and similar discount aggregators provide minimal relief for Prolia specifically because denosumab is not available in a cheap generic formulation and the drug's supply chain is tightly controlled by Amgen.

A biosimilar pathway exists. The FDA has approved denosumab biosimilars including Jubbonti and Wyost (both from Sandoz), and biosimilar uptake may gradually push prices lower. [5] As of mid-2025, biosimilar penetration in the New York outpatient market remains limited, but prescribers should check formulary status with individual payers because some plans have already tiered biosimilars preferentially over branded Prolia.

The practical upshot: almost no commercially insured patient in New York should be paying the $1,500 list price out of pocket. The sections below explain the programs that close that gap.

New York Medicaid Coverage for Prolia (Denosumab)

New York Medicaid covers Prolia for osteoporosis, but prior authorization (PA) is required. The PA criteria generally align with clinical indicators used in the FREEDOM and FREEDOM Extension trials: a documented T-score of -2.5 or below, or a history of low-trauma fracture, or both. [1] Some managed Medicaid plans operating in New York also require evidence that the patient has tried or is contraindicated to a bisphosphonate before approving denosumab.

The New York State Department of Health's Medicaid Drug Utilization Review criteria specify that the prescribing clinician must document diagnosis of osteoporosis, serum calcium within normal limits before initiation, and the planned monitoring schedule. Clinicians can submit PA requests through the eMedNY system or through their payer's provider portal.

Once approved, Medicaid beneficiaries typically pay $0 to $3 per injection at an in-network site of care. Medicaid Advantage plans and mainstream managed care organizations (MCOs) such as Healthfirst, MetroPlus, and Fidelis Care follow the same PA framework but may have additional step-therapy requirements. Providers should confirm the specific MCO's criteria before submitting a PA for a patient enrolled in one of those plans.

Dual-eligible patients (Medicare and Medicaid) receive Prolia under Medicare Part B, with Medicaid filling the 20% cost-sharing gap, effectively resulting in a $0 patient cost at compliant providers.

Commercial Insurance Coverage in New York

Most commercial insurers operating in New York cover Prolia under the medical benefit rather than the pharmacy benefit because the drug is administered by injection in a clinical setting. Coverage under the medical benefit means the drug's reimbursement is tied to a provider's administered drug fee schedule, not the pharmacy tier structure. [6]

Major plans in New York including Empire BlueCross BlueShield, UnitedHealthcare, Aetna, Cigna, and MVP Health Care list denosumab as a covered specialty drug, typically on Tier 3 or Tier 4 of the formulary when billed under pharmacy benefit, or reimbursed under the medical benefit at a percentage of average sales price (ASP) plus a modest administration fee when billed by a physician or infusion center.

Key coverage considerations for New York patients:

• Prior authorization is standard across virtually all commercial plans. Expect to document T-score, fracture history, and, in some plans, prior bisphosphonate use.
• Step therapy requirements vary. Some plans require documented intolerance to alendronate or risedronate before approving denosumab.
• The administration site matters. Office-based injection and hospital outpatient department injection may be billed differently, affecting patient cost-sharing.

The American Association of Clinical Endocrinology (AACE) 2020 guidelines state that "denosumab is recommended as first-line pharmacological therapy in patients with postmenopausal osteoporosis who have a very high fracture risk or who cannot tolerate or absorb oral bisphosphonates." [7] That guideline language can strengthen a PA letter when an insurer demands clinical justification.

The Amgen FIRST STEP Copay Assistance Program

Amgen's FIRST STEP program is the most direct cost-reduction tool for commercially insured patients in New York. Eligible patients pay $0 per dose, with Amgen covering the remaining copay up to the program's annual cap. [4]

Eligibility requires that the patient:

• Has commercial insurance that covers Prolia (Medicaid and Medicare are excluded by federal anti-kickback rules)
• Is a resident of the United States
• Meets Amgen's income and enrollment criteria at the time of application

Enrollment is completed through the prescriber's office or directly at the Amgen website. The card is applied at the point of dispensing or at the provider's billing department for in-office injections. For patients whose plan covers Prolia under the medical benefit, the savings program works differently: the provider bills the plan, and Amgen reimburses the patient's cost-sharing portion after the fact through a mail-in or online claim.

Patients who lose commercial insurance or whose plan drops Prolia from formulary mid-year should contact Amgen's patient support line immediately. A gap in denosumab therapy exceeding six to eight months substantially increases vertebral fracture risk, as documented in a 2017 Osteoporosis International analysis of post-discontinuation fracture patterns. [8]

Are There Other Discount Programs for New York Patients?

Beyond the FIRST STEP card, New York patients have several additional avenues.

Amgen Safety Net Foundation. This program provides Prolia at no cost to uninsured or underinsured patients who meet income thresholds (generally at or below 500% of the federal poverty level). Patients apply through their prescriber's office. Processing typically takes two to four weeks, so clinicians should initiate applications well before a dose is due.

New York State Pharmaceutical Assistance for the Aged and Disabled (EPIC). EPIC supplements drug coverage for New York residents aged 65 or older who do not qualify for full Medicaid. EPIC can reduce out-of-pocket costs for Medicare Part D drugs, though Prolia billed under Part B is handled separately through supplemental Medigap or Medicaid.

340B Program Sites. Federally qualified health centers (FQHCs) and qualifying hospitals participating in the 340B drug pricing program can acquire Prolia at a significantly reduced acquisition cost and may pass some of those savings to uninsured or underinsured patients. New York has a dense network of 340B-eligible sites, particularly in New York City, Buffalo, and Rochester. Patients who receive care at an FQHC should ask whether the site is 340B-enrolled.

The following decision framework summarizes which assistance pathway applies by insurance status for a New York patient in 2026:

| Insurance Status | Primary Cost Pathway | Estimated Patient Cost | |---|---|---| | Commercial insurance | Amgen FIRST STEP copay card | $0 per dose | | Medicare Part B | Medicare covers 80%; Medigap or Medicaid covers remainder | $0 to ~$60 per dose | | New York Medicaid | Covered with PA | $0 to $3 per dose | | Uninsured, income <500% FPL | Amgen Safety Net Foundation | $0 per dose | | Uninsured, income above limit | 340B site or compounded denosumab (503A) | Varies; see below |

Compounded Denosumab in New York: Is It Legal?

Yes, compounded denosumab is legal in New York, but the legal and clinical picture is more nuanced than a simple yes. Compounding pharmacies operating under Section 503A of the Federal Food, Drug, and Cosmetic Act may compound denosumab on a patient-specific basis when a licensed prescriber submits a valid prescription and a documented clinical need. [9]

In New York, 503A pharmacies are also subject to oversight by the New York State Board of Pharmacy, which requires compliance with United States Pharmacopeia (USP) chapters on sterile compounding (USP 797) and hazardous drugs (USP 800). A compounding pharmacy that cannot demonstrate compliance with those standards should not be used for a biologic like denosumab.

Several important caveats apply:

• Compounded denosumab is not FDA-approved and has not been evaluated in the same large clinical trials as branded Prolia or its approved biosimilars. The FDA's concern about compounded biologics centers on bioequivalence, stability, and immunogenicity, as outlined in FDA guidance on compounding biologics. [9]
• Branded Prolia and its FDA-approved biosimilars have full pharmacovigilance data. Compounded preparations do not.
• Some New York 503A pharmacies offering compounded denosumab quote $0 per month (or very low per-dose prices) relative to the $1,500 list price of branded Prolia. That cost difference is real, but patients and prescribers should weigh it against the absence of outcome data for the compounded product.
• Prescribers in New York who order compounded denosumab for a patient should document the clinical rationale and confirm the pharmacy's 503A registration and USP 797 compliance status before signing the prescription.

The FDA has not placed denosumab on its 503A Bulks List, meaning it is not a nominated or approved bulk substance for routine compounding. Prescribers should verify current regulatory status with the FDA's compounding resources page before writing such a prescription. [9]

Telehealth Prescribing of Prolia in New York

New York permits telehealth prescribing of Prolia. A licensed New York prescriber can conduct a video or telephone visit, review the patient's DXA scan results, fracture history, and calcium/vitamin D status, and write a prescription for denosumab without an in-person encounter. [10]

The prescription itself, however, requires an in-person injection. Denosumab is a subcutaneous injection that can be self-administered or administered by a home health nurse, but most payers require the injection to occur at a clinical site to bill under the medical benefit. Patients who prefer in-office administration should confirm with their provider whether a brief in-person visit is required only for the injection.

Telehealth platforms operating in New York, including HealthRX, can manage the full prescribing and PA workflow remotely. The clinician orders baseline labs (serum calcium, creatinine, and 25-OH vitamin D), reviews imaging, writes the Prolia prescription, and coordinates with a local pharmacy or infusion site for injection. Follow-up visits to monitor for hypocalcemia and jaw osteonecrosis risk can also occur via telehealth. [11]

The 2022 American Society for Bone and Mineral Research (ASBMR) task force position on osteoporosis management notes that telehealth has expanded access to fracture risk assessment and pharmacotherapy in underserved areas, a pattern relevant to rural New York counties where endocrinology access is limited. [12]

Monitoring Requirements That Affect Total Cost

The purchase price of Prolia is only part of the cost calculation. Guidelines recommend specific monitoring that adds to the annual expense.

Before each injection, clinicians should confirm that serum calcium is within normal limits. Hypocalcemia is the most common serious adverse effect of denosumab, with the FDA label noting that it occurred in 0.05% of patients in the FREEDOM trial. [1,2] Patients with chronic kidney disease (eGFR <30 mL/min) face substantially higher hypocalcemia risk and may need more frequent calcium monitoring.

Dental evaluation before initiating denosumab is standard practice because of the risk of medication-related osteonecrosis of the jaw (MRONJ). The American Dental Association estimates MRONJ incidence with antiresorptive therapy at 0.001% to 0.01% per year in osteoporosis patients, rising with duration of therapy. [13] A pre-treatment dental clearance visit is a legitimate additional cost that patients should factor into their planning.

DXA scans are typically performed at baseline and every one to two years during therapy. In New York, a DXA scan at an academic medical center or private radiology group costs $150 to $400 without insurance. Medicare reimburses DXA at approximately $130 under the current fee schedule for outpatient facilities.

Medicare Part B Coverage for Prolia in New York

Medicare Part B covers Prolia as a physician-administered drug under the "incident to" billing rules. The drug is reimbursed at ASP plus 6% when administered in a physician's office or at ASP plus 6% in a hospital outpatient department, though the hospital outpatient department rate may be subject to the Outpatient Prospective Payment System (OPPS) adjustment. [6]

After the Part B deductible ($240 in 2024, with annual adjustments), Medicare covers 80% of the allowed amount. The remaining 20% is the patient's responsibility unless covered by a Medigap supplemental plan or New York Medicaid for dual-eligible patients.

For a drug reimbursed at ASP of approximately $1,300 (which is below the list price after mandatory Medicaid rebates and market adjustments), the 20% coinsurance equals roughly $260 per injection or $520 per year for a patient without supplemental coverage. That figure is well within the range where Medigap Plan G or Plan N provides meaningful savings.

Medicare Part D does not typically cover Prolia because Part D covers only pharmacy-dispensed drugs, and Prolia is classified as a Part B drug when administered by a provider. Patients who pick up a Prolia prescription at a retail pharmacy and administer it at home may find it covered under Part D instead, but this pathway is less common in New York clinical practice.

Clinical Evidence Supporting Denosumab Use

The cost and coverage discussion rests on a foundation of strong clinical evidence. The FREEDOM trial (N=7,868 postmenopausal women with osteoporosis) showed that denosumab 60 mg every six months reduced new vertebral fractures by 68% (RR 0.32; 95% CI 0.26 to 0.41; P<0.001), hip fractures by 40% (RR 0.60; 95% CI 0.37 to 0.97; P=0.04), and nonvertebral fractures by 20% (RR 0.80; 95% CI 0.67 to 0.95; P=0.01) over 36 months compared with placebo. [1]

The FREEDOM Extension study followed patients for up to 10 years of continuous denosumab therapy and demonstrated sustained fracture risk reduction with continued bone mineral density gains, with no evidence of a therapeutic plateau at the lumbar spine or total hip. [14] That long-term data set is part of the clinical rationale for why PA denials based solely on duration of therapy are difficult to justify under current evidence.

A 2022 JAMA Internal Medicine analysis found that adherence to osteoporosis pharmacotherapy in the United States is poor, with fewer than 50% of patients remaining on therapy at 12 months after initiation. [15] Cost is consistently cited as the leading modifiable barrier. For New York patients, pairing the Amgen FIRST STEP program with telehealth-based follow-up may address both the financial and logistical barriers simultaneously.

The Endocrine Society's 2019 clinical practice guideline on osteoporosis recommends denosumab as a second-line agent after bisphosphonates in most patients, but acknowledges it as an appropriate first-line choice when bisphosphonates are contraindicated, poorly tolerated, or when the patient has a very high fracture probability on FRAX assessment. [16]

What Happens If You Stop Denosumab?

Discontinuation planning deserves its own section because the cost of stopping therapy incorrectly can be higher than the cost of staying on it. The FDA Drug Safety Communication from 2022 warns that patients who discontinue denosumab without transitioning to an antiresorptive agent (typically a bisphosphonate) face a rapid reversal of bone mineral density gains and a measurable increase in vertebral fracture risk within 12 to 18 months. [2]

A 2017 analysis published in Osteoporosis International documented that fracture rates after denosumab discontinuation exceeded those in the placebo group of the original FREEDOM trial in some subgroups, suggesting the drug's cessation may create a period of heightened vulnerability. [8] This is not hypothetical: case series from European and North American centers have reported multiple simultaneous vertebral fractures in patients who stopped denosumab without a transition plan.

The standard clinical approach in New York endocrinology and primary care practices is to administer one to two doses of zoledronic acid (5 mg IV) or switch to oral alendronate (70 mg weekly) approximately six months after the last Prolia injection if therapy is being discontinued. [16] That transition adds cost but is considered standard of care. Prescribers should discuss the discontinuation plan with patients at the time of initiation, not only when stopping becomes necessary.